Eckert & Ziegler inks deal with Bicycle Therapeutics

Berlin, Germany-based radioisotopes specialist Eckert & Ziegler today announced a comprehensive strategic partnership with the USA’s Bicycle Therapeutics (Nasdaq: BCYC), which is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology.

Under the agreement, Eckert & Ziegler will supply various radioisotopes and will develop as well as manufacture Bicycle Therapeutics’ radiopharmaceutical molecules, called Bicycle Radio Conjugates (BRC molecules). The companies have not disclosed any financial terms of the deal

Bicycle Therapeutics’ proprietary molecules, known for their small size and unique structure, are designed to precisely and selectively deliver a range of therapeutic payloads to their chosen targets, engage targets previously considered inaccessible by conventional therapeutic approaches and therefore address significant unmet medical needs in patients. Eckert & Ziegler's state-of-the-art GMP facility in Berlin will play a key role in ensuring the high-quality manufacture and reliable supply of Bicycle Therapeutics’ BRC molecules for clinical trials.